Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.7352W HIGH $11.80
Volume
642.41 K
Value Traded
6.35 M
Short % Float
19.27%
+2.99%Week
-7.42%1 Month
-6.82%3 Month
-18%6 Month
-58.17%5 Year
+21.36%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
450.76 M
EPS (TTM)
-0.86
P/E Ratio
-
Ent. Value
162.57 M
Total Shares
52.36 M
Float Shares
44.34 M
Insiders
13.63%
Institutions
93.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PRTA Catalyst Timeline
Dated clinical, regulatory and corporate events for Prothena Corporation plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prothena Corporation plc
668Total events
13Upcoming
111Tier-1 (high impact)
2012 to 2029Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Participation in H.C. Wainwright 4th Annual BioConnect Investor Conference
▲Fast Track DesignationcoramitugDesignation
Fast Track designation for coramitug in ATTR-CM
ATTR amyloidosis with cardiomyopathysource ↗
▲Milestone PaymentcoramitugCorporate
$50 million clinical milestone payment from Novo Nordisk related to Phase 3 enrollment
ATTR amyloidosis with cardiomyopathysource ↗
◆Oral PresentationPrasinezumabPresentation
Oral presentation at AD/PD 2026: Modeling Parkinson's Disease Progression to Quantify Long-Term Treatment Effects via the Concept of Time Saved
Parkinson's diseasesource ↗
◆Poster PresentationPrasinezumabPresentation
Poster presentation at AD/PD 2026: Sustained Effect on Prasinezumab on Parkinson's Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update
Parkinson's diseasesource ↗
▲Fast Track DesignationBMS-986446Designation
Fast Track designation for BMS-986446 in Alzheimer's disease
Alzheimer's diseasesource ↗
▲Runway Guidance UpdateCorporate
Updated full year 2026 net cash used guidance to $18-$23 million (from $50-$55 million); expects year-end cash ~$273 million
▲Fast Track DesignationcoramitugDesignation
FDA grants Fast Track Designation for coramitug in ATTR-CM
ATTR amyloidosis with cardiomyopathysource ↗
▲PublicationPrasinezumabPresentation
PADOVA Phase 2b results for prasinezumab published in The Lancet
early Parkinson's diseasesource ↗
●Equity OfferingCorporate
Prothena repurchased 1,454,898 ordinary shares in Q2 2026 under share repurchase program
▲Oral PresentationPrasinezumabPresentation
Modeling Parkinson's Disease Progression to Quantify Long-Term Treatment Effects via 'Time Saved' using PASADENA OLE data
Parkinson's diseasesource ↗
▲Poster PresentationPrasinezumabPresentation
Sustained Effect on Motor Progression in OLE of PASADENA Trial, 5-Year Update
Parkinson's diseasesource ↗
▲Oral PresentationBMS-986446Presentation
Safety, Tolerability, PK, and Immunogenicity in Healthy Participants Including Japanese Ethnicity
Alzheimer's diseasesource ↗
▲Milestone PaymentcoramitugCorporate
$50.0 million milestone payment from Novo Nordisk related to ongoing Phase 3 trial for coramitug
ATTR amyloidosis with cardiomyopathy (ATTR-CM)source ↗
▲Milestone PaymentPRX019Corporate
Potential $105M aggregate clinical milestone payments from partners in 2026
neurodegenerative diseasessource ↗
▲Fast Track DesignationcoramitugDesignation
FDA granted Fast Track designation for coramitug in ATTR-CM
ATTR amyloidosis with cardiomyopathysource ↗
▲Fast Track DesignationBMS-986446Designation
FDA granted Fast Track designation for BMS-986446 as treatment for Alzheimer's disease
Alzheimer's diseasesource ↗
◆Trial InitiationPrasinezumabTrial
Roche to initiate Phase 3 PARAISO trial of prasinezumab
early-stage Parkinson's diseasesource ↗
▲Trial InitiationPrasinezumabTrial
Roche to initiate Phase 3 development of prasinezumab
early-stage Parkinson's diseasesource ↗
◆Poster PresentationPresentation
Prothena poster on TDP-43 CYTOPE in ALS mouse model at Neuroscience 2025
ALSsource ↗
●Corporate ApprovalCorporate
Shareholder approval to reduce share capital to support share redemption program
◆Oral PresentationcoramitugPresentation
Novo Nordisk to present Phase 2 coramitug results at AHA Scientific Sessions
ATTR amyloidosis with cardiomyopathysource ↗
◆Trial InitiationcoramitugTrial
Novo Nordisk initiated Phase 3 CLEOPATTRA trial of coramitug
ATTR amyloidosis with cardiomyopathysource ↗
▲Fast Track DesignationBMS-986446Designation
BMS-986446 granted Fast Track designation by FDA
Alzheimer's diseasesource ↗
▲Trial InitiationPrasinezumabTrial
Roche initiated Phase 3 PARAISO trial of prasinezumab
early-stage Parkinson's diseasesource ↗
▲Trial InitiationcoramitugTrial
Novo Nordisk initiated Phase 3 CLEOPATTRA trial of coramitug
ATTR amyloidosis with cardiomyopathysource ↗
◆Full ResultsPRX012Clinical Data
Phase 1 ASCENT clinical program results announced
early symptomatic Alzheimer's diseasesource ↗
◆Topline ReadoutPRX012Clinical Data
Initial data from Phase 1 ASCENT clinical trials of PRX012
Alzheimer's diseasesource ↗
◆Primary CompletionBMS-986446Trial
Primary completion of Phase 1 subcutaneous administration trial of BMS-986446
Alzheimer's diseasesource ↗
◆Topline ReadoutcoramitugClinical Data
Phase 2 clinical trial results for coramitug
ATTR amyloidosis with cardiomyopathysource ↗
●Trial CompletionBMS-986446Trial
Phase 1 subcutaneous formulation trial completion for BMS-986446
Alzheimer's diseasesource ↗
▼Program DiscontinuationbirtamimabDiscontinuedCorporate
Discontinuation of birtamimab program
◆Topline ReadoutPRX012Clinical Data
Multiple clinical readouts from Phase 1 ASCENT trials starting mid-2025
Alzheimer's diseasesource ↗
◆Timing GuidancePrasinezumabPresentation
Roche to determine next steps with health authorities
Parkinson's diseasesource ↗
▼Primary Endpoint MissedbirtamimabDiscontinuedClinical Data
Phase 3 AFFIRM-AL trial did not meet primary endpoint of time to all-cause mortality
AL amyloidosissource ↗
Past FDA Catalysts and PDUFA Decisions
How PRTA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-19 | TDP-43 CYTOPE® | Pre-clinical data presentation | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C40 / 100
Pipeline Score
$234M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.5x
rNPV / MCap
Top 39%
Micro Cap(rank 257 of 658)
Percentile Rank
Prothena Corporation plc carries a moderate pipeline score (40/100), with $586M risk-adjusted pipeline value, led by Prasinezumab in Parkinsons Disease (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prasinezumab Monoclonal antibodyNCT03100149 | Parkinsons Disease | Phase 3 | ACTIVE NOT_RECRUITING | 1,802 | Dec 1, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRTA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| prasinezumab | Parkinson's disease | Phase 3 | 2026-03-23 | two years less advanced in disease severity five years after the start of the trial; estimated two years of ‘time saved’Read More | Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SCULLY WILLIAM P10% Owner | Buy | 100,000 314,000 held | $8.57 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRTA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 1.5 % (-16.7 %) | 11.19 M | 1.14 M | -5.41% ( -65.41 K) |
PRTA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-12-18 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRTA ranks across every disease it competes in
Competitive Position is a premium feature
See how PRTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRTA News
PRTAProthena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prothena Corporation is set to participate in the H.C. Wainwright 28th Annual Global Investment Conference. This event presents an opportunity for the company to engage with investors and discuss its latest developments. The conference is a significant platform for Prothena to highlight its strategic initiatives and future prospects.
Read more →PRTAProthena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena has announced its financial results for the second quarter and the first half of 2026. The report includes key business highlights, although specific details on performance metrics were not provided in the announcement. The company continues to focus on its strategic initiatives moving forward.
Read more →PRTAProthena to Report Second Quarter 2026 Financial Results on August 6
Prothena Corporation has announced that it will report its financial results for the second quarter and the first half of 2026 on August 6, 2026. This update highlights the company's commitment to keeping investors informed about its financial performance. The report will provide insights into Prothena's operational progress and financial health.
Read more →PRTAProthena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc reported strong financial results for Q1 2026, including a net income of $32.7 million, a significant improvement from the previous year's loss. The company highlighted positive developments in its partnered Phase 3 clinical programs, particularly for prasinezumab in Parkinson's disease and coramitug in ATTR-CM. Prothena also updated its financial guidance, projecting lower cash burn and an increase in cash reserves by year-end.
Read more →PRTAProthena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will not hold a conference call following the release, consistent with its previous practices. Prothena is recognized for its expertise in protein dysregulation and is advancing a pipeline targeting various neurodegenerative diseases.
Read more →PRTA▲ +6.7%on this newsshared move
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation announced that the FDA has granted Fast Track Designation to coramitug, an investigational antibody for treating ATTR amyloidosis with cardiomyopathy. This designation aims to expedite the development of drugs addressing serious conditions. Coramitug is currently being evaluated in the Phase 3 CLEOPATTRA trial, which could significantly impact treatment options for this life-threatening disease.
Read more →PRTAProthena Announces Leadership Team Updates
Prothena Corporation plc has announced updates to its leadership team, promoting Annie Kingston to Chief Strategy Officer and Michael Isaacs to General Counsel. Kingston's promotion is effective immediately, while Isaacs will take over following the departure of Michael Malecek in June. The leadership changes aim to enhance Prothena's growth strategy and corporate legal functions.
Read more →PRTAProthena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena Corporation presented significant clinical updates on prasinezumab for Parkinson's disease and BMS-986446 for Alzheimer's disease at the AD/PD™ 2026 conference. Data indicated that prasinezumab may effectively slow disease progression, while BMS-986446 was found safe and well-tolerated in healthy participants. These findings support ongoing clinical studies for both treatments.
Read more →PRTAProthena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation has announced the receipt of a $50 million milestone payment from Novo Nordisk for achieving an enrollment target in the Phase 3 CLEOPATTRA trial for Coramitug, a potential treatment for ATTR amyloidosis with cardiomyopathy. To date, Prothena has earned $150 million of the total $1.2 billion available under their agreement with Novo Nordisk. The trial is expected to involve approximately 1280 participants, with primary completion anticipated in 2029.
Read more →PRTA▲ +8.4%on this news
Prothena Announces up to $100 Million Share Repurchase Plan
Prothena Corporation plc has announced a share repurchase plan allowing for the buyback of up to $100 million of its ordinary shares. As of December 31, 2025, the company reported a strong cash position of $308.4 million with no debt. The plan is set to expire on December 31, 2026, and may be adjusted based on market conditions.
Read more →PRTAProthena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, revealing a net loss of $244.1 million. The company is actively engaged in key clinical trials, including those for treatments in Parkinson's and Alzheimer's diseases. Prothena's cash position remains strong at $308.4 million, and it anticipates potential clinical milestone payments amounting to $105 million from its strategic partners in 2026. The report also notes significant restructuring and tax-related expenses that have impacted its overall financial performance.
Read more →PRTAProthena Reports Third Quarter 2025 Financial Results and Business Highlights
Prothena Corporation plc announced its financial results for the third quarter of 2025, highlighting a cash position of $331.7 million amidst a net loss of $36.5 million. The company is advancing various clinical trials, including collaborations with Roche and Bristol Myers Squibb for treatments targeting Parkinson's and Alzheimer's diseases. Notably, Prothena has the potential to receive up to $105 million in clinical milestone payments related to ongoing collaborations. Despite challenges like reduced revenue and a significant net loss, Prothena's progress in drug development is promising.
Read more →PRTAProthena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Prothena Corporation announced results from its Phase 1 ASCENT clinical program assessing PRX012 for Alzheimer's disease. The program demonstrated promising efficacy with significant reductions in amyloid plaque and generally well-tolerated treatment. However, the results also revealed a higher incidence of ARIA-E events compared to existing therapies. Prothena is considering partnerships to further develop PRX012 and its related compounds.
Read more →PRTA▲ +12.7%on this news
Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation announced that Novo Nordisk will advance coramitug into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This is a significant milestone, as coramitug is a potential first-in-class amyloid depleter antibody. The advancement is expected to address the unmet needs of patients who suffer from this disease. Prothena stands to earn up to $1.2 billion from the agreement, reflecting strong collaboration opportunities with Novo Nordisk.
Read more →PRTAProthena Reports Second Quarter 2025 Financial Results and Business Highlights
Prothena Corporation plc reported its second quarter 2025 financial results, highlighting a net loss of $125.8 million with total revenues significantly down from the prior year. The company emphasized advancements in their pipeline, including the progression of prasinezumab into Phase 3 development for Parkinson's disease and anticipated initial data from PRX012 for Alzheimer's. Prothena also expressed potential financial benefits from upcoming clinical milestone payments but acknowledged significant restructuring charges related to program discontinuation. Overall, the financial outlook remains challenging amidst ongoing operational developments.
Read more →PRTA▲ +11.4%on this news
Prothena s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson s Disease DUBLIN, Ireland, June 15, 2025 Prothena Corporation plc (NASDAQ:PRTA), today announced partner Roche will advance
Prothena Corporation plc and its partner Roche have announced the advancement of prasinezumab into Phase III development for early-stage Parkinson's disease. This decision follows positive data from the Phase IIb PADOVA study and open-label extensions. While prasinezumab showed potential clinical benefits, such as trends towards reduced motor progression, it missed the primary endpoint's statistical significance. Ongoing trials will further evaluate the drug's efficacy and safety over extended periods.
Read more →PRTAProthena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Prothena Corporation announced that its Phase 3 AFFIRM-AL clinical trial for birtamimab in AL amyloidosis patients did not meet the primary endpoint, leading to the decision to discontinue its development. Both primary and secondary endpoints were not met, raising concerns among stakeholders. Despite this setback, Prothena plans to focus on upcoming pipeline updates and further clinical trials, including those related to Alzheimer's disease. Plans for a workforce reduction and cost management have also been initiated in light of the trial results.
Read more →PRTAProthena Reports First Quarter 2025 Financial Results and Business Highlights
Prothena Corporation reported its financial results for Q1 2025, including a net loss of $60.2 million, an improvement from the previous year's loss. The company highlighted several upcoming clinical milestones, including topline results expected in 2Q 2025 from the Phase 3 AFFIRM-AL trial for birtamimab, and multiple readouts from the Phase 1 ASCENT trials for PRX012. Collaborations with Roche continue to showcase promising data for the treatment of early Parkinson's disease. Prothena maintains a strong cash position of $418.8 million while advancing its research and development pipeline in neurodegenerative diseases.
Read more →About Prothena Corporation plc
Headquarters77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2, D02 VK60
BIOPHARMAWATCH ELITE PLUS
Trade the next PRTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime